The University of Chicago Joint Section of Hematology/Oncology at Mitchell Hospital and Michael Reese Hospital, Chicago, Illinois has excellent cancer research resources with 22 full-time faculty positions, 6 research associates, 6 private practitioners in oncology, nurse oncologists and 13 fellows in addition to multiple laboratory technicians and secretaries. There are three in-patient units; a 24 bed hematology unit at The University of Chicago Medical Center (UCMC), a 24 bed oncology unit at UCMC, and a 36 bed hematology/oncology unit at Michael Reese Medical Center (MRMC). In addition, a data management unit exists at each medical center. We bring a long tradition of excellent independent research to the CALGB. Our clinical expertise in lymphoma, leukemia, cytogenetics and lung cancer will mesh well with CALGB interests. The size of our program will allow rapid patient accrual. In the first 6 months we were able to enter 36 pts. into CALGB protocols with a variety of diseases; 1 acute leukemia pt., 2 lymphoma pts., 2 sarcoma pts., 16 breast cancer pts., 12 lung cancer pts., and 3 mesothelima pts. Our entry efficiency is 100% on the first 22 pts. evaluated by the CALGB central office. No pts. were ineligible, cancelled or lost to follow-up. The addition of 2 adjuncts in the past month should allow for a projected accrual of 80 pts. for the first year. In addition to our patient accrual, our participation in CALGB activities has been excellent. Several members of our group are on 7 different committees and have been actively participating in CALGB on-going activities. Our strong laboratory interests in cancer pharmacology and pharmacokinetics, cytogenetics and gene mapping, cell biology, and molecular biology should provide a fertile foundation for the development of new studies. The strength of our application is in our 4 institutions; our more than 35 faculty with many well-known senior faculty, our strong core laboratories, and our enthusiastic participation. This application is requesting appropriate funds for a very active, strong member of the CALGB.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA041287-02
Application #
3558376
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1986-09-30
Project End
1988-03-31
Budget Start
1987-04-01
Budget End
1988-03-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050

Showing the most recent 10 out of 224 publications